Our results suggesting that SARA is an active participant in both SMAD2-inhibitory and SMAD3-stimulatory effects on cancer cell invasion are consistent with the possibility that the targeting of SARA/SMAD binding would be unlikely to provide significant therapeutic benefits for cancer patients. Here, SMAD3 is linked to cancer.